Literature DB >> 24703804

Breast-conservative surgery followed by radiofrequency ablation of margins decreases the need for a second surgical procedure for close or positive margins.

Isabel T Rubio1, Stefania Landolfi2, Meritxell Molla3, Javier Cortes4, Jordi Xercavins5.   

Abstract

BACKGROUND: Excision of breast cancer followed by radiofrequency ablation (eRFA) is a technique designed to increase negative margins in breast-conservative surgical procedures. The objective of this study is to analyze the impact of eRFA in avoiding a second surgical procedure for close or positive margins after a breast-conservative surgical procedure.
MATERIAL AND METHODS: From February 2008 to May 2010, 20 patients were included. After lumpectomy, the eRFA was performed in the lumpectomy cavity, and biopsies from each margin from the radial ablated cavity walls were obtained. Biopsy samples were assessed for tumor viability.
RESULTS: eRFA was successful in 19 of 20 patients. In all patients, the devitalized tissue extended beyond a 5- to 10-mm radial depth of the biopsy sample. Overall, 6 patients (31%) had margins < 2 mm, 4 of them with < 1 mm margin. All 6 of these patients had no tumor viability according to analysis of biopsy samples stained with 2,3,5-triphenyltetrazolium chloride. At a median follow-up of 46 months, no local recurrence had been found.
CONCLUSION: This study supports the feasibility of eRFA treatment. In our study, the eRFA method has spared 31% of patients from undergoing a re-excision surgical procedure, and it may, in the long-term, reduce local recurrences.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Breast cancer; Lumpectomy cavity; Radiofrequency ablation; Recurrences; Reoperation

Mesh:

Year:  2014        PMID: 24703804     DOI: 10.1016/j.clbc.2014.02.002

Source DB:  PubMed          Journal:  Clin Breast Cancer        ISSN: 1526-8209            Impact factor:   3.225


  1 in total

Review 1.  Symptomatic Fibroid Management: Systematic Review of the Literature.

Authors:  Yelena Havryliuk; Robert Setton; John J Carlow; Barry D Shaktman
Journal:  JSLS       Date:  2017 Jul-Sep       Impact factor: 2.172

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.